Trevi Therapeutics (TRVI) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Trevi Therapeutics (NASDAQ: TRVI) in the last few weeks:

• 3/10/2025 – Trevi Therapeutics was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a $29.00 price target on the stock, up previously from $9.00.
• 3/10/2025 – Trevi Therapeutics had its price target raised by analysts at HC Wainwright from $7.50 to $12.50. They now have a “buy” rating on the stock.
• 3/10/2025 – Trevi Therapeutics had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
• 2/24/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.

Trevi Therapeutics Stock Up 41.2 %

NASDAQ:TRVI opened at $6.07 on Tuesday. The firm has a market cap of $466.58 million, a PE ratio of -13.80 and a beta of 0.90. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The company’s 50-day moving average price is $4.18 and its two-hundred day moving average price is $3.54.

Hedge Funds Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after purchasing an additional 3,283,684 shares in the last quarter. Woodline Partners LP lifted its position in shares of Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after purchasing an additional 2,606,370 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $58,000. Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $66,000. Finally, Two Sigma Investments LP acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $560,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.